News

Understanding childhood cancer in sub-Saharan Africa


 

Photo by Aurimas Rimsa

Children in The Gambia

Researchers say they have published the most extensive data ever collected on childhood cancer in sub-Saharan Africa.

On the African continent, only South Africa operates a childhood cancer registry on the national level.

Researchers brought together data from 16 of the smaller, local registries, collecting this information for the first time and presenting it in an accessible format.

The data were published in ecancermedicalscience.

Examining the data in context allowed the researchers to notice trends in cancer incidence. For example, they found that, in Blantyre, Malawi’s second-largest city, the cumulative risk of a child developing Burkitt lymphoma is 2 in every thousand.

The researchers called this incidence “remarkable” and noted that the global research community is largely unaware of this.

“Everything starts with awareness,” said study author Cristina Stefan, global clinical leader of oncology for Roche Diagnostics International Ltd of Switzerland and director of the African Medical Research and Innovation Institute.

“It is highly necessary to publicize these data, which, at the moment, represent the best image of the malignant disease in children in the respective regions.”

The researchers also noted that factors such as the prevalence of malaria and the Epstein-Barr virus contribute to the unique epidemiology of childhood cancer in Africa.

“Our colleagues can learn that the patterns and distribution of cancers in Africa are totally different from Europe, and there is a need for further research into the roles of factors such as genetic predispositions and the influence of infections and other comorbidities in the evolution of cancer,” Dr Stefan said.

“We have learned many universal lessons about data collection as we prepared this work. Our hope is that the publication of this monograph will open the forums for future discussions and that the work will be referenced for the better understanding of cancer in children in Africa and used to improve outcomes for children affected there.”

Recommended Reading

M13-982 trial in del(17p) CLL: High, durable response rates to venetoclax
MDedge Hematology and Oncology
ASCO updates guidelines on antiemetic use in cancer patients
MDedge Hematology and Oncology
FDA grants drug breakthrough designation for AML
MDedge Hematology and Oncology
Team makes ‘fundamental’ AML discovery
MDedge Hematology and Oncology
Developing better mouse models
MDedge Hematology and Oncology
Predicting response to treatment in AML, MDS
MDedge Hematology and Oncology
High ORR with sequential regimen in CLL
MDedge Hematology and Oncology
CHMP recommends midostaurin for FLT3+ AML, SM
MDedge Hematology and Oncology
AYA cancer survivors struggle with social functioning
MDedge Hematology and Oncology
Modified, CB-derived NK cells target CLL and BL
MDedge Hematology and Oncology